Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06311942 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06311942 · ClinicalTrials.gov record · last posted 2024-05-07

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

StatusRecruiting
PhasePhase 4
Started2024-04-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-03-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-05-05
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06311942
Lead Sponsor Chen Xiaoping
Conditions HCC
Enrollment 300 participants
Start Date 2024-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-07